Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy

Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Diarrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms OnTARGET
  • Sponsors Jaguar Health; Napo Pharmaceuticals

Most Recent Events

  • 26 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 21 Jun 2024 According to a Jaguar Health media release, company will report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024.
  • 11 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top